Thomas Hospital
Acute Care Hospitals · Voluntary non-profit - Private
750 Morphy Avenue
Fairhope, AL 36532
- Emergency services
- Medicare overall rating: 2 of 5 stars
At a glance
- Clinicians who list this hospital
- 597
- Physicians (MD and DO)
- 439
- Residents and fellows in training (full-time equivalents, fiscal year 2025)
- 41
- Medical groups
- 15+
Quality and patient experience
- Medicare overall rating (of 5)
- 2
- Patient survey rating (of 5)
- 3
- Patients who would definitely recommend it (national average 71%)
- 72%
Compared with the national rate
| Measures | Better | Same | Worse |
|---|---|---|---|
| Deaths after treatment | 0 | 6 | 2 |
| Safety of care (infections, complications) | 0 | 7 | 0 |
| Readmissions and return visits | 1 | 6 | 2 |
Number of Medicare quality measures where this hospital’s rate is statistically better than, the same as (no different from), or worse than the national rate.
What patients said
- Doctors communicated well 3 of 5 stars
- Nurses communicated well 3 of 5 stars
- Explained medicines 2 of 5 stars
- Discharge information 3 of 5 stars
- Clean 2 of 5 stars
- Quiet at night 4 of 5 stars
From 582 patient surveys (HCAHPS), period ending 09/30/2025.
Medicare “birthing-friendly” hospital: takes part in a maternity care quality program and follows recommended safety practices.
Source: CMS Care Compare (Hospital General Information; Patient survey HCAHPS). Ratings describe the hospital overall, not individual doctors.
Physicians by specialty
- Internal Medicine 53
- Family Medicine 48
- Emergency Medicine 31
- Radiology 27
- OB-GYN (Obstetrics & Gynecology) 22
- Orthopedic Surgery 16
- Neurology 16
- Urology 14
- General Surgery 14
- ENT (Otolaryngology) 12
- Anesthesiology 12
- Pulmonology 12
- Interventional Cardiology 10
- Gastroenterology 10
- Hospitalist 10
- Cardiology 8
- Hematology & Oncology 8
- Surgical Oncology 7
- Sports Medicine 7
- Neurosurgery 7
- Vascular Surgery 7
- Cardiothoracic Surgery 7
- Endocrinology & Diabetes 7
- Infectious Disease 6
- Radiation Oncology 6
- Physical Medicine & Rehabilitation (PM&R) 6
- Pathology 6
- Pain Medicine 5
- Rheumatology 4
- Critical Care Medicine 4
- Medical Oncology 4
- Spine Surgery 3
- Ophthalmology 3
- Hand Surgery 3
- Cardiac Electrophysiology 3
- Nephrology (Kidney) 2
- Allergy & Immunology 2
- Urogynecology 2
- Colorectal Surgery 2
- Plastic Surgery 2
- Gynecologic Oncology 2
- Joint Replacement Surgery 1
- General Practice 1
- Facial Plastic Surgery 1
- Hepatology 1
- Addiction Medicine 1
- Sleep Medicine 1
- Dermatology 1
- Retina Specialist 1
- Psychiatry 1
Other clinicians
Medical groups whose clinicians work here
- Imc-Diagnostic and Medical Clinic LLC 70
- Eastern Shore Anesthesia, P.c. 46
- Imc-Hospitalists LLC 35
- Foley Clinic Corp. 30
- Baldwin Emergency Physicians, P.c.. 27
- Alabama Coastal Radiology PC 24
- Southern Orthopaedic Alliance PLLC 24
- Cardiology Associates of Mobile Inc 20
- Imc-Cardio-Thoracic and Vascular Surgical Associates LLC 19
- Imc-Eastern Shore Adult Medicine, LLC 19
- USA Health Physician Billing Services LLC 18
- Baldwin Bone and Joint P C 18
- Urology Associates of Mobile, P.a. 16
- Gulf Health Hospitals Inc 16
- Imc-Cancer Surgery of Mobile, LLC 16
Number of each group’s clinicians who list this hospital.
Industry-funded research here
Drug and device companies reported $512,638 in research payments to this hospital in 2025 for 12 studies.
- An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Part…
Merck Sharp & Dohme LLC · $144,298 - A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvaluma…
Amgen Inc. · $121,597 - A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
Merck Sharp & Dohme LLC · $99,793 - A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
Genentech, Inc. · $70,943 - A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination with Tremelimumab Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in P…
AstraZeneca Pharmaceuticals LP · $19,106 - Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Boston Scientific Corporation · $18,516 · Recruiting - Global Symplicity Registry Define
Medtronic, Inc. · $11,354 - BIOFLOW-VII
Biotronik Inc. · $9,222 - A phase iii, randomized, double-blind study of tira plus atezo in adjuvant nsclc
Genentech, Inc. · $8,500 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
AbbVie Inc. · $4,048 · Active, not recruiting - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · $3,611 · Active, not recruiting - DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patient…
Boehringer Ingelheim Pharmaceuticals, Inc. · $1,650
From CMS Open Payments research payments to this hospital as a teaching hospital. Payments to affiliated universities or research foundations are reported under those names. All industry-funded trials →
Other hospitals in the same county
Sources: CMS Hospital General Information and Doctors and Clinicians Facility Affiliation (Care Compare), CMS certification number 010100. Counts are clinicians who list this hospital with Medicare; they include part-time and visiting clinicians and aren’t staff totals. Residents and beds are from the hospital’s Medicare cost report. Ratings are Medicare’s, not ours.